Moshin Bajwa, MD
Pulmonary Disease · Houston, TXNPI 1497743462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,022 of the $23,310 with a category attached, or 60.2%. 35 manufacturers reported payments, led by GSK at 55.5% of the total. Reporting peaked in 2020 at $9,545 and has fallen 76.7% since, to $2,226 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 670 payments — averaging $34.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$13K
- Electromed, Inc.$2K
- Viiv Healthcare Company$2K
- Actelion Pharmaceuticals US, Inc.$919
- AstraZeneca$892
- Mylan Specialty L.p.$862
- plus $4K from 29 others
Across 1 payment — averaging $84,177 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$84K
What the payments were for
- Speaking & faculty fees$14,02260%
- Food & beverage$9,07139%
- Education$2171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 97 | $12,931 |
| Electromed, Inc. | 280 | $2,492 |
| Viiv Healthcare Company | 1 | $1,600 |
| Actelion Pharmaceuticals US, Inc. | 49 | $919 |
| AstraZeneca | 43 | $892 |
| Mylan Specialty L.p. | 8 | $862 |
| Boehringer Ingelheim | 26 | $519 |
| Sanofi | 10 | $509 |
| Philips North America LLC | 24 | $368 |
| Genentech USA, Inc. | 16 | $277 |
| Inspire Medical Systems, Inc. | 19 | $237 |
| Insmed, Inc. | 12 | $203 |
| Grifols USA, LLC | 11 | $196 |
| United Therapeutics Corporation | 11 | $127 |
| Sunovion Pharmaceuticals Inc. | 14 | $112 |
| Mallinckrodt Hospital Products Inc. | 5 | $107 |
| Pulmonx Corporation | 5 | $107 |
| Bayer | 5 | $96 |
| Regeneron Healthcare Solutions, Inc. | 5 | $94 |
| Amgen | 4 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Biosense Webster, Inc. | 1 | $68 |
| Viatris Specialty LLC | 2 | $56 |
| Paratek Pharmaceuticals, Inc. | 3 | $53 |
| Johnson & Johnson(2 entities) | 3 | $52 |
| Novartis | 2 | $39 |
| Merck | 3 | $38 |
| Inogen, Inc. | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Optinose US, Inc. | 1 | $20 |
| Gilead | 1 | $14 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$11,700
- Yupelri$722
- DUPIXENT$336
How this compares
$23,310 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 22 | $513,478 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 455 | $418,567 |
| OfevNintedanib Esylate | 26 | $345,306 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 274 | $245,514 |
| OpsumitMacitentan | 11 | $141,764 |
| Breo ElliptaFluticasone/Vilanterol | 95 | $53,082 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $45,389 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $28,059 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $22,311 |
| Spiriva RespimatTiotropium Bromide | 17 | $19,545 |
| EliquisApixaban | 17 | $11,010 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $8,297 |
| Roflumilast | 74 | $7,477 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 266 | $7,318 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $5,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $919 | $655,24233 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $12,931 | $503,415605 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $519 | $410,239118 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $892 | $267,825317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.